Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

Yu SUN; Honghai ZHANG; Jiang LONG; Shoupeng SHENG; Jiasheng ZHENG; Yonghong ZHANG

doi:10.3969/j.issn.1001-5256.2022.10.016

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2286-2289

PDF( 1758 KB)

Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.10.016

Center of Interventional Oncology and Liver Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Scientific Research and Cultivation Plan of Beijing Municipal Hospitals (PX2022067);

Natural Science Foundation of Beijing Municipality (7191004);

Beijing Key Laboratory of Biomarkers for Infectious Diseases (BZ0373)

More Information

Corresponding author: ZHANG Yonghong, 13810108505@163.com(ORCID: 0000-0002-1357-7891)
Received Date: 2022-03-02
Accepted Date: 2022-04-05
Published Date: 2022-10-20

Abstract

Abstract

Objective To investigate the influence of the interval between transcatheter arterial embolization (TAE) and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma. Methods A total of 70 patients with hepatocellular carcinoma who received treatment in Beijing YouAn Hospital, Capital Medical University, from January 2019 to June 2020 were enrolled and divided into observation group (radiofrequency ablation was performed on the day or the second day of TAE) and control group (radiofrequency ablation was performed at 1-2 weeks after TAE) using a random number table, with 35 patients in each group. The independent samples t-test was used for comparison of continuous data between two groups, and the paired t-test was used for comparison of observation indicators before and after surgery; the chi-square test was used for comparison of categorical data between two groups. Results The observation group had a significantly shorter length of hospital stay than the control group (7.80±2.76 days vs 14.31±2.19 days, t=-10.93, P < 0.001). There were no significant differences between the observation group and the control group in complete ablation rate (95.12% vs 95.00%, χ²=0.001, P=0.980), incidence rate of adverse reactions (25.71% vs 20.00%, χ²=0.324, P=0.569), and 1-year recurrence rate (11.43% vs 14.29%, χ²=0.128, P=0.721), and there were also no significant differences in laboratory markers between the two groups before and after treatment (all P > 0.05). Conclusion TAE combined with sequential radiofrequency ablation at a short interval is safe and effective in the treatment of small hepatocellular carcinoma and can significantly shorten the length of hospital stay and reduce hospital costs, and therefore, it holds promise for clinical application.
- Carcinoma, Hepatocellular,
- Embolization, Therapeutic,
- Local Ablation,
- Treatment Outcome

FullText(HTML)

References(14)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	ZHOU R, LI S, WAN WJ, et al. Comparison of clinical prognosis between surgical resection and local thermal ablation for small liver cancer[J/CD]. Chin J Hepat Surg (Electronic Edition), 2021, 10(3): 258-262. DOI: 10.3877/cma.j.issn.2095-3232.2021.03.006. 周瑞, 李珊, 万文军, 等. 手术切除与局部热消融治疗小肝癌预后比较[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(3): 258-262. DOI: 10.3877/cma.j.issn.2095-3232.2021.03.006.
[3]	LIU YY, LAI JX. Minimally invasive interventional therapy for liver cancer[J/CD]. Chin J Hepat Surg: Electronic Edition, 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001. 刘允怡, 赖俊雄. 肝癌微创介入治疗[J/CD]. 中华肝脏外科手术学电子杂志, 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001.
[4]	KIM JW, KIM JH, WON HJ, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone[J]. Eur J Radiol, 2012, 81(3): e189-e193. DOI: 10.1016/j.ejrad.2011.01.122.
[5]	XIONG K, BAI F, CHEN DN, et al. Comparison of the effcacy and safety of the combined treatment of transcatheter arterial chemoembolization and radiofrequency ablation with transcatheter arterial chemoembolization or radiofrequency ablation treatment alone in patients with primary hepatic carcinoma in China[J]. Chin Health Resources, 2018, 21(3): 271-274, 279. DOI: 10.13688/j.cnki.chr.2018.17765. 熊琨, 白飞, 陈丹妮, 等. 中国原发性肝癌肝动脉化疗栓塞术和射频消融联合治疗与单独治疗的有效性和安全性比较[J]. 中国卫生资源, 2018, 21(3): 271-274, 279. DOI: 10.13688/j.cnki.chr.2018.17765.
[6]	ZHANG M, HUANG J, XIAO HX, et al. Time node study of sequential treatment of primary hepatocellular carcinoma by hepatic artery embolization chemotherapy combined with microwave ablation guided by ultrasound[J]. J Clin Exp Med, 2021, 20(10): 1080-1083. DOI: 10.3969/j.issn.1671-4695.2021.10.020. 张明, 黄君, 肖华旭, 等. 肝动脉栓塞化疗联合超声引导下微波消融序贯治疗原发性肝癌的时间节点研究[J]. 临床和实验医学杂志, 2021, 20(10): 1080-1083. DOI: 10.3969/j.issn.1671-4695.2021.10.020.
[7]	National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
[8]	CAI DS, ZHU WD, LI Z. Superselective hepatic arterial embolization associated with radiofrequency ablation in treating primary small hepatocellular carcinoma[J]. J Intervent Radiol, 2008, 17(3): 218-219. DOI: 10.3969/j.issn.1008-794X.2008.03.020. 蔡东顺, 朱望东, 李哲. 超选择性肝动脉栓塞与射频消融术联合治疗小肝癌[J]. 介入放射学杂志, 2008, 17(3): 218-219. DOI: 10.3969/j.issn.1008-794X.2008.03.020.
[9]	WANG Y, MA L, SHENG S, et al. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer[J]. Minim Invasive Ther Allied Technol, 2018, 27(6): 355-364. DOI: 10.1080/13645706.2018.1462833.
[10]	OH JH, SINN DH, CHOI GS, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria[J]. Ann Surg Treat Res, 2020, 99(4): 238-246. DOI: 10.4174/astr.2020.99.4.238.
[11]	SI ZM, WANG GZ, QIAN S, et al. Combination therapies in the management of large (≥5 cm) hepatocellular carcinoma: Microwave ablation immediately followed by transarterial chemoembolization[J]. J Vasc Interv Radiol, 2016, 27(10): 1577-1583. DOI: 10.1016/j.jvir.2016.02.014.
[12]	JIN H, WANG H, LI G, et al. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma[J]. J Int Med Res, 2020, 48(10): 300060520961260. DOI: 10.1177/0300060520961260.
[13]	GUO WP, WANG J, GUAN YW, et al. TACE combined with microwave ablation versus radical surgical resection for the treatment of small HCC: a comparison study[J]. J Intervent Radiol, 2019, 28(7): 642-646. DOI: 10.3969/j.issn.1008-794X.2019.07.007. 郭玮平, 王杰, 管一伟, 等. 肝动脉化疗栓塞联合微波消融与外科根治性切除治疗小肝癌的对照研究[J]. 介入放射学杂志, 2019, 28(7): 642-646. DOI: 10.3969/j.issn.1008-794X.2019.07.007.
[14]	LI Z, HAO D, JIAO D, et al. Transcatheter arterial chemoembolization combined with simultaneous cone-beam computed tomography-guided microwave ablation in the treatment of small hepatocellular carcinoma: Clinical experiences from 50 procedures[J]. Acad Radiol, 2021, 28(Suppl 1): s64-s70. DOI: 10.1016/j.acra.2020.08.036.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(9)

1.	迟洵，刘思思，陈巧，胡玥，王伟仙. 不同营养筛查工具对肝硬化患者营养筛查适用性的网状Meta分析. 中国全科医学. 2025(11): 1395-1402 .
2.	祁喜平，马蓉霞，李静，扈玫琳. 活血化瘀中医干预法对肝硬化营养不良患者的应用效果及血清营养指标影响. 中华养生保健. 2024(05): 23-26 .
3.	任婷婷，郭俊，高露露，童婉秋，王怡斌，王线妮. 降低全身型重症肌无力患者营养不良发生率. 中国卫生质量管理. 2024(04): 81-86 .
4.	迟学彭，任新华，张耀庭，张驰，陈璎珞，王琦. NRS2002与RFH-NPT营养风险筛查工具对失代偿期肝硬化住院患者的适用性. 中国肝脏病杂志(电子版). 2024(03): 65-68 .
5.	黄颖，余小平，陈怡，李云秀，刘大凤，高锦凤，韩斌，曾义岚. 失代偿期肝硬化患者营养不良诊断模型的探讨. 四川医学. 2023(02): 117-123 .
6.	杜旭芳，李超，王鹏，姚佳，杨柳青，侯慧敏. 个体化营养管理策略联合延续护理模式对肝硬化病人营养状况和生活质量的影响. 护理研究. 2023(22): 4096-4100 .
7.	付志鹏，郑盛，杨涓. 肝硬化患者营养评价方法研究进展. 国际医药卫生导报. 2023(23): 3341-3344 .
8.	陈春霞，徐冠华，崔志明. 营养评估在肝癌患者治疗中的应用研究进展. 南京医科大学学报(自然科学版). 2022(10): 1488-1494 .
9.	胡吉蕾，汤善宏，林宁. 终末期肝病合并肌肉衰减症的早期识别和营养干预. 中华临床营养杂志. 2022(05): 310-317 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (461) PDF downloads(38)

Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.10.016